Advertisement

Correction of the Cancer Therapy-Induced Anemia by the Grape Polyphenol Concentrate Enoant

  • Galina Solyanik
  • Volodymyr I. Mizin
  • Olga Pyaskovskaya
  • Natalia Banakchevich
  • Yuriy A. Ogay
Conference paper
Part of the NATO Science for Peace and Security Series A: Chemistry and Biology book series (NAPSA)

Abstract

Anticancer drugs do not possess sufficient specificity of action. Each cytostatic agent shows a wide spectrum of side effects that limit the efficacy of therapy and make the quality of life for a cancer patient worse. It forces scientists to search for new pharmacological agents for the correction/prevention of side effects. The polyphenolic compounds are naturally occurring phytochemicals that could be considered as potentially effective protectors of cancer chemotherapy toxicity. The main goal of the study was to study the ability of the grape polyphenol concentrated product Enoant to reduce hematotoxicity of cancer cytotoxic chemotherapy. In a preclinical study, the influence of Enoant on both hematotoxicity and the efficacy of cisplatin administered into Lewis lung carcinoma bearing mice was investigated. Enoant provided a significant protection against cisplatin-induced hematotoxicity by increasing red blood cell production and normalizing leukocyte levels in tumor-­bearing mice. Enoant did not stimulate tumor growth and metastasis and did not reduce the efficacy of cisplatin-based therapy. Twenty cancer patients with anemia (averaged hemoglobin level was 85.8±0.8 g/L) were included in the clinical study. The correction of anemia during the first stage of investigation was conducted using either iron-containing drugs or erythropoietin. This gave the possibility to begin the course of cancer chemotherapy in 6.7±1.0 days when the hemoglobin level reached 94.6±1.8 g/L. Before the next course of anticancer treatment, the patients received Enoant (total dose of polyphenols was 5 g), that resulted in an 11 % increase of hemoglobin levels (p<0.05) up to 103.5±2.8 g/L. Thus, Enoant is an effective and safe agent for the treatment of cancer associated anemia. Enoant is well accepted by patients. Its safety, convenient oral form and palatability make it possible to carry out an effective correction of anemia at home.

Keywords

Negative Control Group Lewis Lung Carcinoma Tumor Cell Inoculation Erythropoietin Receptor Stimulate Tumor Growth 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    La Porta CA (2004) Cellular targets for anticancer strategies. Curr Drug Targets 5:347–355PubMedCrossRefGoogle Scholar
  2. 2.
    Chibaudel B, Tournigand C, André T et al (2012) Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 4:75–89PubMedCrossRefGoogle Scholar
  3. 3.
    Aguilar LK, Guzik BW, Aguilar-Cordova E (2011) Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 112:1969–1977PubMedCrossRefGoogle Scholar
  4. 4.
    Dueñas-González A, García-López P, Herrera LA et al (2008) The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 7:82PubMedCrossRefGoogle Scholar
  5. 5.
    MacKenzie SH, Clark AC (2008) Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets 8:98–109PubMedCrossRefGoogle Scholar
  6. 6.
    Liu WM (2008) Enhancing the cytotoxic activity of novel targeted therapies – is there a role for a combinatorial approach? Curr Clin Pharmacol 3:108–117PubMedCrossRefGoogle Scholar
  7. 7.
    Nanda A, St Croix B (2004) Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 16:44–49PubMedCrossRefGoogle Scholar
  8. 8.
    Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17:1359–1370PubMedCrossRefGoogle Scholar
  9. 9.
    Schiff D, Wen PY, van den Bent MJ (2009) Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 6:596–603PubMedCrossRefGoogle Scholar
  10. 10.
    Nazer B, Humphreys BD, Moslehi J (2011) Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 124:1687–1691PubMedCrossRefGoogle Scholar
  11. 11.
    Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616–1634PubMedCrossRefGoogle Scholar
  12. 12.
    Kulkarni S, Ghosh SP, Hauer-Jensen M et al (2010) Hematological targets of radiation damage. Curr Drug Targets 11:1375–1385PubMedCrossRefGoogle Scholar
  13. 13.
    Caro JJ, Salas M, Ward A et al (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:2214–2221PubMedCrossRefGoogle Scholar
  14. 14.
    Schwartz RN (2007) Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 64:S5–S13PubMedCrossRefGoogle Scholar
  15. 15.
    Steensma DP (2008) Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol 26:1022–1024PubMedCrossRefGoogle Scholar
  16. 16.
    Goldrick A, Olivotto IA, Alexander CS et al (2007) Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer. Curr Oncol 14:227–233PubMedCrossRefGoogle Scholar
  17. 17.
    Laurie SA, Jeyabalan N, Nicholas G et al (2006) Association between anemia arising during therapy and outcomes of chemoradiation for limited small-cell lung cancer. J Thorac Oncol 1:146–151PubMedCrossRefGoogle Scholar
  18. 18.
    Obermair A, Cheuk R, Horwood K et al (2003) Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: effect on progression-free survival. Int J Gynecol Cancer 13:633–639PubMedCrossRefGoogle Scholar
  19. 19.
    Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25:43–46PubMedGoogle Scholar
  20. 20.
    Calabrich A, Katz A (2011) Management of anemia in cancer patients. Future Oncol 7:507–517PubMedCrossRefGoogle Scholar
  21. 21.
    Montoya L (2007) Managing hematologic toxicities in the oncology patient. J Infus Nurs 30:168–172PubMedCrossRefGoogle Scholar
  22. 22.
    Glaspy JA (2008) Erythropoiesis-stimulating agents in oncology. J Natl Compr Canc Netw 6:565–575PubMedGoogle Scholar
  23. 23.
    Rodgers GM (2011) Treatment of chemotherapy-induced anemia. Clin Adv Hematol Oncol 9:147–148PubMedGoogle Scholar
  24. 24.
    Aapro M, Jelkmann W, Constantinescu SN et al (2012) Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 106(7):1249–1258PubMedCrossRefGoogle Scholar
  25. 25.
    Bennett CL, Silver SM, Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914–924PubMedCrossRefGoogle Scholar
  26. 26.
    Henke M, Mattern D, Pepe M et al (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708–4713PubMedCrossRefGoogle Scholar
  27. 27.
    Fandrey J, Dicatob M (2009) Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. Oncologist 14:34–42PubMedCrossRefGoogle Scholar
  28. 28.
    Curin Y, Andriantsitohaina R (2005) Polyphenols as potential therapeutical agents against cardiovascular diseases. Pharmacol Rep 57:97–107PubMedGoogle Scholar
  29. 29.
    Brisdelli F, D'Andrea G, Bozzi A (2009) Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 10:530–546PubMedCrossRefGoogle Scholar
  30. 30.
    Sen G, Mandal S, Saha RS et al (2005) Therapeutic use of quercetin in the control of infection and anemia associated with visceral leishmaniasis. Free Radic Biol Med 38:1257–1264PubMedCrossRefGoogle Scholar
  31. 31.
    Carstena RE, Bachand AM, Baileya SM et al (2008) Resveratrol reduces radiation-induced chromosome aberration frequencies in mouse bone marrow cells. Radiat Res 169:633–638CrossRefGoogle Scholar
  32. 32.
    Mikstacka R, Rimando AM, Ignatowicz E (2010) Antioxidant effect of trans-resveratrol, pterostilbene, quercetin and their combinations in human erythrocytes in vitro. Plant Foods Hum Nutr 65:57–63PubMedCrossRefGoogle Scholar
  33. 33.
    Wang DX, Liu P, Chen YH et al (2008) Stimulating effect of catechin, an active component of Spatholobus suberectus Dunn, on bioactivity of hematopoietic growth factor. Chin Med J (Engl) 121:752–755Google Scholar
  34. 34.
    Takano F, Tanaka T, Aoi J et al (2004) Protective effect of (+)-catechin against 5-fluorouracil-induced myelosuppression in mice. Toxicology 201:133–142PubMedCrossRefGoogle Scholar
  35. 35.
    Jeong JY, Silver M, Parnes A et al (2011) Resveratrol ameliorates TNFα-mediated suppression of erythropoiesis in human CD34(+) cells via modulation of NF-κB signalling. Br J Haematol 155:93–101PubMedCrossRefGoogle Scholar
  36. 36.
    Bohlius J, Weingart O, Trelle S et al (2006) Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol 3:152–164PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Galina Solyanik
    • 1
  • Volodymyr I. Mizin
    • 2
  • Olga Pyaskovskaya
    • 1
  • Natalia Banakchevich
    • 3
  • Yuriy A. Ogay
    • 4
  1. 1.R.E. Kavetsky Institute of Experimental PathologyOncology and Radiobiology of the National Academy of Sciences of UkraineKyivUkraine
  2. 2.Division of Health and RehabilitationCrimean State Humanitarian UniversityYalta, CrimeaUkraine
  3. 3.Kyiv Municipal Oncological ClinicMinistry of Public Health of UkraineKyivUkraine
  4. 4.Private Enterprise “Ressfood”Yalta, CrimeaUkraine

Personalised recommendations